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Abstract Cardiovascular disease is a major public health
problem worldwide. Its growing burden is particularly omi-
nous in Asia, due to increasing rates of major risk factors such
as diabetes, obesity and smoking. There is an urgent need for
early identification and treatment of individuals at risk of
adverse cardiovascular events. Plasma extracellular vesicle
proteins are novel biomarkers that have been shown to be
useful in the diagnosis, risk stratification and prognostication
of patients with cardiovascular disease. Ongoing parallel
biobank initiatives in European (the Netherlands) and Asian
(Singapore) populations offer a unique opportunity to validate
these biomarkers in diverse ethnic groups.
Cardiovascular disease is a global problem
Cardiovascular disease accounted for 30 % of an estimated 58
million deaths globally from all causes in 2005 [1]. It is
important to recognise that a substantial proportion of these
deaths (46%) occurred in individuals under 70 years of age, in
their productive years of life; in fact, 79 % of the disease
burden attributed to cardiovascular disease is in this age group
[2]. Moreover, between 2006 and 2015, deaths due to non-
communicable diseases (half of which are due to cardiovas-
cular disease) are expected to increase by 17 % [1]. This
projected increase is most prominent in Asia due to a very
large, ageing population, increasing exposure to aWesternised
diet, and rapidly increasing rates of diabetes mellitus [3].
Early detection of patients at risk and early institution of
effective treatment may help to ease the mortality and mor-
bidity burden of cardiovascular disease. To achieve this, tools
for early diagnosis and risk stratification of patients are ur-
gently needed.
Ischaemic heart disease is a major cardiovascular cause of
death worldwide. Improved early diagnosis in patients with
chest pain in or before the emergency department would
reduce the burden on the hospitals. Furthermore, in an ageing
population with improved outcome after myocardial infarc-
tion, the number of patients with an elevated risk for a second
cardiovascular event is increasing but identification of patients
at high risk of recurrent events remains difficult. Increasing
survival following acute coronary events also leads to more
patients living to develop heart failure (HF). HF, the final
common pathway of cardiac insults, is a serious syndrome
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due to inability of the heart to provide adequate circulation for
the body’s needs or only able to do so at increased cardiac
filling pressures. It is the cardiovascular syndrome projected to
increase most [4] in the USAwith the largest attendant loss of
productivity and increase in direct medical cost in the next
20 years [4]. Europe and Asia show similar data [5, 6], with a
rapid increase in disease burden on society. Diagnosis is diffi-
cult and the prognosis in HF remains poor. Evidence-based
therapy of proven efficacy has been introduced over the last
25 years but mortality and readmission rates remain high.
Plasma extracellular vesicles
Extracellular vesicles, including microvesicles, microparticles
and exosomes [7], are abundant in plasma. Extracellular ves-
icles are secreted by all cells, especially after stimulation of
inflammatory cells. These vesicles are important in cell to cell
communication in a variety of processes including coagula-
tion [8], antigen presentation [9] and tissue damage [10].
Plasma extracellular vesicles can be easily isolated from fro-
zen plasma or serum and contain protein, miRNA and RNA
depending on source and stimulus.
Extracellular vesicles that play a role in the initiation of
thrombus formation are of major interest in cardiovascular dis-
ease pathogenesis, since thrombosis is the major underlying
cause of cardiovascular events. In this process, monocyte-
derived extracellular vesicles play an important role. Tissue
factor (TF), as an important initiator of thrombosis, was found
in vesicles that are positive for the monocyte marker CD14
(Fig. 1). In vitro studies using endothelial cells (EC) showed
that these TF-containing vesicles do not only initiate thrombosis
but also adhere to the EC that results in increased EC
thrombogenicity via elevation of TF activity in the EC and
decrease of tissue factor pathway inhibitor and thrombomodulin
[11]. This procoagulant activity, with monocyte-derived circu-
lating TF as its main source, was associated with coronary artery
disease [12] and in stent thrombosis [13].
If extracellular vesicle proteins are involved in cardiovas-
cular events, then plasma vesicle protein content might be an
important biomarker source for prognosis and prediction of
cardiovascular events.
Extracellular vesicle proteins for diagnosis of ACS
Circulating miRNAs are, at least partly, derived from extra-
cellular vesicles and have been used in the diagnosis of acute
coronary syndrome (ACS, [14]). Extracellular vesicle protein
levels, however, have only recently been described to carry
information in the presence of ACS [15]. Following a prote-
omics discovery approach, we demonstrated in a chest pain
cohort of 471 patients that pIgR, Cystatin C (CST3), C5a and
total vesicle protein concentration are associated with the
presence of ACS. Comparisons of this association between
male and female patients reveal these markers to be highly
associated with ACS in males but not with ACS in females.
This striking difference is in agreement with an increasing
body of evidence that women tend to have lower rates of
coronary artery occlusions and have a more preserved left
Fig. 1 Diagram showing an overview of the potential plasma extracel-
lular vesicle procoagulant activity. Subpopulations of extracellular vesi-
cles (EVs) in the plasma involved in coagulation are thought to have three
origins: monocyte-derived EVs (blue), platelet-derived EVs (red) and
endothelial cell-derived EVs (green) as outlined in the enlarged EV 3-
colour pie chart. EVs contain proteins involved in coagulation and
fibrinolysis. For coagulation TF is the key initiator of the coagulation
cascade and forms a complex with factor VIIa (FVIIa). This complex
activates factor IX (FIX) and factor X (FX). The activated factor X (FXa)
further cleaves prothrombin into thrombin that converts fibrinogen into
fibrin to form clot. For fibrinolysis, the plasmin inhibitors SERPING1 and
SERPINF2 have been identified in EVs and inhibit the breakdown of a
fibrin via fibrinolysis. Abbreviations: EV, extracellular vesicle; TF, tissue
factor; PSGL-1, P-selectin glycoprotein ligand-1; PS, phosphatidylserine;
P-sel, P-selectin; E-sel, E-selectin
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ventricular function. Women, however, also have a higher
mortality and a worse prognosis following MI compared with
men. The established difference in extracellular vesicle pro-
tein levels associated with ACS identifies vesicles as an ex-
cellent biomarker source for gender-specific diagnosis and
prognosis of ACS. Furthermore, this might help in under-
standing the underlying gender differences in the pathophys-
iology of ACS.
Extracellular vesicle proteins for prognosis of secondary
cardiovascular events
The number of survivors of a first cardiovascular event is on
the rise globally with a rapid increase in Asia. These patients
are at high risk for a second cardiovascular event even after
adequate control of risk factors. The number and type of extra-
cellular vesicles that are CD31+/Annexin V+ positive were
associatedwith an increased risk for secondary events consisting
of myocardial infarction, percutaneous coronary intervention
(PCI), coronary artery bypass graft (CABG), stroke and vascular
mortality [16].
For the first time, the protein content of all plasma extra-
cellular vesicles and its association with secondary cardiovas-
cular events were studied in a large clinical cohort [17].
Comparing plasma extracellular vesicles of patients with a
secondary cardiovascular event to gender- and age-matched
patients without a second cardiovascular event, we identified
four vesicle proteins that were different between the two
groups. These vesicle proteins were Cystatin C, SerpinG1,
SerpinF2 and CD14 and were validated in the SMARTcohort.
This revealed that three of these vesicle proteins (Cystatin C,
SerpinF2 and CD14) were associated with future cardiovas-
cular events after correction of risk factors such as age, gender,
smoking and eGFR.
For this, measurement of plasma extracellular vesicle pro-
tein levels has the potential to stratify patients at risk for
secondary events on top of risk factors.
There is much uncertainty over the relative contribution
of platelets to the overall circulating extracellular vesicle
population. Platelets are a key intermediary in the blood
extracellular vesicle landscape because their function is
readily and rapidly modified by platelet-directed medica-
tions. The ongoing Stratifying risk with Metabolomics
And platelet Reactivity Testing in Acute Coronary Syn-
drome (SMART-ACS) study, initiated in Singapore, in-
cludes platelet reactivity testing of more than 1000 patients
undergoing invasive management of ACS, using imped-
ance aggregometry (multiple electrode aggregometry,
Roche Diagnostics, Indianapolis, IN) and follow up for
secondary cardiovascular events. This will allow us to
investigate how platelet-directed medications may poten-
tially modify the content of the plasma extracellular ves-
icle population and its association with secondary events.
Caucasian and Asian cardiovascular biobanking
The identification and validation of new biomarkers is high-
ly dependent on the availability of patient cohorts with
detailed phenotypic characterisation. Important ethnic differ-
ences have been described in the susceptibility, risk factors,
and outcomes with cardiovascular disease. For example:
Indian men in the UK have an adjusted hazard ratio of
1.45 (CI: 1.29 to 1.63) for cardiovascular disease while
Chinese men in the UK have an adjusted hazard ratio of
0.51 (CI: 0.32 to 0.83) compared with Caucasian men [18].
Among Southeast Asian patients with HF in Singapore,
Indians and Malays have been shown to suffer worse out-
comes than Chinese [19] although the reasons remain
unclear [20]. The ADHERE-Asia Pacific Registry showed
that compared with other multicentre registries in the US
and Europe, Asian patients hospitalised with HF were youn-
ger and had more severe clinical features.
For this, we initiated the (ongoing) biobanking efforts in
both Singapore and the Netherlands (Fig. 2). In 2008, the
NL (Caucasian) SG (Chinese, Malay, Indian)Fig. 2 Overview of ongoing
cardiovascular biobanking in
Singapore and the Netherlands.
Red boxes indicate matched
biobank studies, green boxes
indicate work in progress of
matching Singapore and Dutch
biobank studies, numbers indicate
patients included ~ June 2013
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design of the AtheroExpress [21] collecting tissue, plasma and
blood cells with a follow-up for secondary cardiovascular
events was used to start up the Singapore AtheroExpress at
the National University Heart Center Singapore (NUHCS).
This Singapore biobank is collecting, besides atherectomy
samples, also aortic punctures during CABG next to plasma
and blood cells, and follows patients up for secondary cardio-
vascular events. Aortic punctures and plasma are now also
collected at the UMC Utrecht in Pegasus using the same
design.
Singapore initiated the collection of plasma of patients
undergoing a PCI with follow-up for secondary cardiovascu-
lar events. A year later, the UMC Utrecht ‘mirror’ biobank of
PCI patients was initiated, a collective effort that now includes
over 1000 patients a year.
Work is in progress to match patients with chest pain in the
emergency department of theMeander Hospital in Amersfoort
(Minerva biobank cohort) with chest pain cohorts at NUHCS
and Singapore General Hospital as well as the extensive HF
cohort initiatives in Singapore [22] and Asia [23] with Dutch
heart failure cohorts.
A key advantage of these mirrored cohorts is the implemen-
tation of common data and tissue collection and storage proto-
cols across sites in both countries. This facilitates comparisons
of biomarker profiles between Dutch and Singapore popula-
tions; such an effort is currently ongoing, with measurement of
high sensitivity troponin T, high sensitivity C-reactive protein,
von Willebrand factor, myeloperoxidase and Cystatin C in
1200 Dutch and 1000 Singaporean patients who have under-
gone elective coronary angiography.
Future perspectives
Plasma extracellular vesicle proteins are still in the early stage of
study, mostly aiming to identify and to characterise the
proteomes. Although relatively unexplored due to technical chal-
lenges, vesicle proteins hold promise as mass spectrometry-
based proteomic technology is rapidly emerging for identifica-
tion and quantification of extremely low abundant proteins in a
sample. This has already resulted in identification of vesicle
proteins for the diagnosis of ACS [15] and prognosis of second-
ary cardiovascular events [17] in clinical cohorts. Isolation of
plasma extracellular vesicle subpopulations is expected to lead to
new and better cardiovascular vesicle protein biomarkers in a
new sample set.
This rapidly growing vesicle technology will hold, in com-
bination with the maturation of the biobanks (inclusion of
patients and secondary events) in the Netherlands and Asia,
great promise for new diagnostic and prognostic biomarkers
that take ethnicity and gender into account.
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